Akademska digitalna zbirka SLovenije - logo
(UL)
  • Efficacy and safety of Herbion ivy syrup in patients with cough in acute bronchitis: comparison with a competitive brand with the same composition
    Uranič, Nataša ; Barbič-Žagar, Breda
    Aim of the study: Evaluate the efficacy and safety profile of Herbion ivy syrup in comparison with a competitive brand with the same composition, Prospan syrup, in patients with cough in acute ... bronchitis. Subjects and methods: A total of 126 patients were enrolled in the randomised, open, parallel, comparative and multicentre study. Sixty-three patients were randomised to receive Prospan syrup, and the other 63 to receive Herbion ivy syrup. Both products were taken orally for 7 days according to the prescribed dosing schedule each day of the therapy - 5 ml of syrup three times daily. The efficacy and safety assessments were carried out after 7 days of therapy. Additionally, safety and tolerability evaluation was done at day 4 of therapy and at day 14 (one week after the end of therapy). Results: Improvement of cough was reported in 98.4% of patients in the Herbion and 96.8% of patients in the Prospan group. There was no significant difference between the two active treatments (Fischerʼs exact test; p = 1.00, lower 95% CI - 3.8 %). Complete relief of cough was reported in 16.1% of patients in the Herbion group and in 11.1% of patients in the Prospan group. Both treatments significantly (p < 0.001) reduced cough frequency and severity with comparisonto baseline. The point estimates of mean change of frequency of cough for Herbion ivy syrup and the reference product were 2.03 and 1.86, respectively. The point estimates in cough severity for Herbion and the reference product were -43.6 mm and -42.9 mm, respectively. There was no significant difference between the two active treatments. Both products had very good tolerability. Adverse reactions occurred in 1.6% of patients in the reference product group and in 3.2% of patients in the Herbion group. The difference was not statistically significant. Conclusions: Herbion ivy syrup was demonstrated to be an equally effective and safe therapeutic option as the reference product Prospan syrup for the treatment of cough in patients with acute bronchitis.
    Vir: Evidence-based therapy with Krka's medicines (Str. 156-162)
    Vrsta gradiva - prispevek na konferenci
    Leto - 2014
    Jezik - angleški
    COBISS.SI-ID - 3767921

Vnos na polico